BMC Medicine (Feb 2022)

c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

  • Robert D. Morgan,
  • Cristina Ferreras,
  • Isabel Peset,
  • Egle Avizienyte,
  • Andrew G. Renehan,
  • Richard J. Edmondson,
  • Alexander D. Murphy,
  • Shibani Nicum,
  • Thomas Van Brussel,
  • Andrew R. Clamp,
  • Diether Lambrechts,
  • Cong Zhou,
  • Gordon C. Jayson

DOI
https://doi.org/10.1186/s12916-022-02270-y
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 11

Abstract

Read online

Highlights Tissue microarrays and germline DNA from women recruited to the phase 3 trial, ICON7, underwent quantitative immunofluorescence for c-MET/VEGFR-2 co-expression and genetic sequencing for single nucleotide polymorphisms (SNPs) VEGF-pathway genes. High c-MET/VEGFR-2 co-localisation on tumour tissue independently predicted worse survival in bevacizumab-treated epithelial ovarian cancer. The VEGFR-2 rs2305945 SNPs also independently predict worse survival in bevacizumab-treated epithelial ovarian cancer.

Keywords